Nanovibronix (NASDAQ:FEED) Major Shareholder Purchases $640,800.00 in Stock

Nanovibronix, Inc. (NASDAQ:FEED) major shareholder Christian Michael Glibert bought 240,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 14th. The shares were bought at an average price of $2.67 per share, for a total transaction of $640,800.00. Following the completion of the acquisition, the insider owned 240,000 shares in the company, valued at approximately $640,800. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Nanovibronix Stock Performance

NASDAQ FEED traded down $0.15 during mid-day trading on Wednesday, reaching $2.71. 679,860 shares of the company’s stock traded hands, compared to its average volume of 29,800,780. Nanovibronix, Inc. has a 1-year low of $0.99 and a 1-year high of $162.50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings started coverage on shares of Nanovibronix in a research note on Tuesday, January 27th. They set a “sell (e+)” rating on the stock. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.